C. Lefeuvre-Plesse

578P Tertiary cancer prevention: A national evaluation of the practices and perceptions of hospital-based health care professionals (HHCPs) in charge of the follow-up (FU) care of cancer

T. Ben Ahmed, Lucie Véron, E. Dubois-Delaloge, T. Pudlarz et autres

fr, re (code pays fourni par la source)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, Lisa Belin et autres

PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic with bevacizumab and chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), a placebo-controlled double-blinded …

fr, es, at, cz, be, il, de (code pays fourni par la source)

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, Alexandra Léary, Sandro Pignata, Claire Cropet et autres

BACKGROUND: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular …

fr, it, es, at, jp, be, dk, fi, de, ch, in (code pays fourni par la source)

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Sakiko Nagao, P. Harter, A. Leary, C. Cropet et autres

jp, de, fr, it, es, at, be, fi (code pays fourni par la source)

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Isabelle Laure Ray-Coquard, P. Pautier, S. Pignata, D. Pérol et autres